fenofibrate + orlistat

Fenofibrate + orlistat is a combination of two small molecule drugs used together for the management of obesity and metabolic syndrome, particularly in overweight and obese patients with associated cardiovascular risk factors. Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that primarily lowers triglycerides and modifies lipid profiles by increasing HDL cholesterol and reducing small dense LDL particles. Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption, leading to weight loss. The combination has been shown to have additive or synergistic effects on improving lipid parameters (notably reducing small dense LDL cholesterol and lipoprotein-associated phospholipase A2 activity), body weight, BMI, waist circumference, total cholesterol, LDL cholesterol, triglycerides, glucose metabolism indices (glucose/insulin/HOMA index), and blood pressure in patients with metabolic syndrome[1][2][6]. This combination may be administered as separate agents or potentially as a single formulation[5].